Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, unfortunately, will be rather somber, as we remember our last surviving official mascot, Kirby HaKelev, a sweet and animated companion for many years. Thanks for everything, good boy. But what about you? This is a fine time to catch up a few moving pictures you may have missed or you could support your local library by checking out a few good tales. Or you could simply find time to catch up with someone special. Life is short, you know. Well, whatever you do, have a grand time. But, be safe. Enjoy, and see you soon.

Novartis (NVS) began a lottery this week for its spinal muscular atrophy gene therapy, called Zolgensma, as ethicists and advocates debate the merits and the design of the unusual arrangement, STAT explains. Parents say it is uncomfortable to cast their child’s fate into what felt like a sweepstakes — a kind of bizarre Willy Wonka contest — but if it was a chance to get the drug, it was worth trying. Some ethicists, meanwhile, say that favoring those with the greatest need — meaning the sickest children — would be a more ethical approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.